|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2100045921 |
|
最近更新日期: Date of Last Refreshed on: |
2021-12-04 22:36:28 |
|
注册时间: Date of Registration: |
2021-04-28 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
请于伦理委员会批准后才开始征募参试者,并与我们联系上传伦理批件。 补充维生素D对预防良性阵发性位置行眩晕复发的疗效观察 |
|
Public title: |
The Efficacy of Vitamin D Supplementation on Prevention of the Recurrence of Vertigo in Benign Paroxysmal Positional Vertigo |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
补充维生素D对预防良性阵发性位置行眩晕复发的疗效观察 |
|
Scientific title: |
The Efficacy of Vitamin D Supplementation on Prevention of the Recurrence of Vertigo in Benign Paroxysmal Positional Vertigo |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
杨智玲 |
研究负责人: |
杨智玲 |
|
Applicant: |
Yang Zhiling |
Study leader: |
Yang Zhiling |
|
申请注册联系人电话: Applicant telephone: |
+86 18394013800 |
研究负责人电话:
Study leader's |
+86 18394013800 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
yangzl1986@126.com |
研究负责人电子邮件: Study leader's E-mail: |
yangzl1986@126.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
兰州市东岗西路160号 |
研究负责人通讯地址: |
兰州市东岗西路160号 |
|
Applicant address: |
160 Donggang Road West, Lanzhou, Gansu |
Study leader's address: |
160 Donggang Road West, Lanzhou, Gansu |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
甘肃省人民医院 |
||
|
Applicant's institution: |
Gansu Provincial Hospital |
||
|
研究负责人所在单位: |
甘肃省人民医院 |
||
|
Affiliation of the Leader: |
Gansu Provincial Hospital |
||
|
是否获伦理委员会批准: |
否 |
||
|
Approved by ethic committee: |
No |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
伦理委员会批件附件: Approved file of Ethical Committee: |
||
|
批准本研究的伦理委员会名称: |
|
||
|
Name of the ethic committee: |
|
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2013-08-26 00:00:00 | ||
|
伦理委员会联系人: |
|
||
|
Contact Name of the ethic committee: |
|
||
|
伦理委员会联系地址: |
|
||
|
Contact Address of the ethic committee: |
|
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
||
|
研究实施负责(组长)单位: |
甘肃省人民医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Gansu Provincial Hospital |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
兰州市东岗西路160号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
160 Donggang Road West, Lanzhou, Gansu |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
甘肃省自然科学基金 |
||||||||||||||||||||||
|
Source(s) of funding: |
Natural Science Foundation of Gansu Province |
||||||||||||||||||||||
|
研究疾病: |
良性阵发性位置性眩晕 |
||||||||||||||||||||||
|
Target disease: |
Benign paroxysmal positional vertigo |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
探索性研究/预试验 | ||||||||||||||||||||||
|
Study phase: |
0 |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
研究补充维生素D对预防BPPV复发的疗效。 |
||||||||||||||||||||||
|
Objectives of Study: |
To evaluate the efficacy of Vitamin D supplementation on prevention of the recurrence of BPPV. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1.符合中华医学会耳鼻咽喉科分会BPPV 诊断标准:Dix-Hallpike 试验阳性诊为垂直半规管BPPV,水平滚转试验阳性诊为水平半规管 BPPV,均为特发性BPPV,年龄≥18岁且≤80岁; |
||||||||||||||||||||||
|
Inclusion criteria |
1. In line with the BPPV diagnostic criteria of the Otolaryngology Branch of the Chinese Medical Association (a positive Dix-Hallpike test is diagnosed as vertical semicircular canal BPPV, and a positive horizontal rolling test is diagnosed as horizontal semicircular canal BPPV, all of which are idiopathic BPPV, aged >= 18 and <= 80 years; |
||||||||||||||||||||||
|
排除标准: |
1.合并其它外周眩晕疾病或中枢性眩晕疾病; |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Combined with other peripheral vertigo diseases or central vertigo diseases; |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2021-05-01 00:00:00至 To 2023-02-01 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2021-06-01 00:00:00 至 To 2022-06-01 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
正在进行 Recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
由专门制定的研究员吕芸采用随机序列发生器生成250以内的随机序列数(N=110,A组55,B组55),自动按多组设计转换成组别标记。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
The specially-designed researcher Lu Yun uses a random sequence generator to generate random sequence numbers within 250 (N=110, group A 55, group B 55), and automatically convert them into group tags according to the multi-group design. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
未说明 |
|
Blinding: |
Not stated |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
未说明 请阅读网页注册指南中关于“原始数据共享”的内容。 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
Not stated |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
数据采集由制定的病例记录表和电子采集表两部分组成 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
The data collection consists of two parts: the prepared case record form and the electronic collection form. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |